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To assess the association between variant repeat (VR) interruptions in patients with myotonic
dystrophy type 1 (DM1) and clinical symptoms and outcome measures after cognitive be-
havioral therapy (CBT) intervention.
Methods
Adult patients with DM1 were recruited within the OPTIMISTIC trial (NCT02118779).
Disease-related history, current clinical symptoms and comorbidities, functional assessments,
and disease- and health-related questionnaires were obtained at baseline and after 5 and 10
months. After genetic analysis, we assessed the association between the presence of VR in-
terruptions and clinical symptoms’ long-term outcomes and compared the effects of CBT in
patients with and without VR interruptions. Core trial outcome measures analyzed were:
6-minute walking test, DM1-Activ-C, Checklist Individual Strength Fatigue Score, Myotonic
Dystrophy Health Index, McGill-Pain questionnaire, and Beck Depression inventory—fast
screen. Blood samples for DNA testing were obtained at the baseline visit for determining CTG
length and detection of VR interruptions.
Results
VR interruptions were detectable in 21/250 patients (8.4%)—12 were assigned to the
standard-of-care group (control group) and 9 to the CBT group. Patients with VR interruptions
were significantly older when the first medical problem occurred and had a significantly shorter
disease duration at baseline. We found a tendency toward a milder disease severity in patients
with VR interruptions, especially in ventilation status, mobility, and cardiac symptoms. Changes
in clinical outcome measures after CBT were not associated with the presence of VR
interruptions.
Conclusions
The presence of VR interruptions is associated with a later onset of the disease and a milder
phenotype. However, based on the OPTIMISTIC trial data, the presence of VR interruptions
was not associated with significant changes on outcome measures after CBT intervention.
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Myotonic dystrophy type 1 (DM1) is an autosomal dominant
inherited, clinically heterogeneous chronic progressive multi-
system disorder caused by an expansion of a highly unstable
CTG repeat in the DMPK gene. Overall, the age at onset and
the severity of symptoms are linked to the number of inherited
CTG repeats,1,2 as conventionally analyzed by Southern blot
hybridization of restriction-digested genomic blood DNA.3
Using these methods, the phenotype-genotype correlation is
rather weak and only explains the age at onset in approximately
20%–40% of the variation in age at onset.3–6 However, such
measures of the average CTG repeat length fail to take account
of the age-dependent somatic expansion observed in the blood
DNA,7–9 and estimating the inherited or progenitor allele
length (ePAL, the lower boundary of the expanded allele dis-
tribution) using small-pool PCR8 has been shown to explain
much more of the variability in age at onset (;70%).3 These
data also revealed that the degree of somatic instability is an
individual determinant of the age at onset in DM1.3 Further-
more, large cohort studies have shown that the presence of
variant repeats (VRs) interrupting theDMPKCTG expansions
reduces somatic instability and results in a later age at onset and
delayed progression.10–14 VRs have been identified in 3–11%of
patients with DM1 across various different ethnicities.10,14,15
VRs are located either at the 39 or 59 ends ofDMPK expansions,
and although CCG, CTC, GGC, and CAG interruptions have
been identified, CCG VRs are, by far, the most
common.10–12,15–18 In 2018, Cumming et al.19 described a later
onset of the disease and a milder clinical phenotype in patients
with DM1 with VRs in the OPTIMISTIC cohort.
As part of the OPTIMISTIC trial (NCT0211877920), we
performed an additional analysis on the association between
the presence of VR interruptions and clinical symptoms,
sociodemographic characteristics, and outcome measures af-
ter cognitive behavioral therapy (CBT) intervention. In the
OPTIMISTIC study, we previously demonstrated that most
outcome measures significantly improved after CBT.21 In this
trial, CBT was based on a previously constructed DM1 spe-
cific model of health status. Major determinants of health
status in this model are: chronic fatigue, reduced initiative,
and weak social interactions. Patients in the CBT group were
assigned to a CBT-trained psychologist. After initial assess-
ment of the main neuropsychological symptoms, an in-
dividual overall CBT goal was created by shared decision-
making and using specific tools and modules (goal setting,
getting started, sleep-wake pattern, activity, helpful beliefs,
pain, and optimizing social interactions). Treatment sessions
were conducted in person and by telephone on an individual
frequency between baseline (V2) and month 10 (V4).21
Methods
Protocol and Patient Population
Data analyzed in this work were collected within the OP-
TIMISTIC trial, a multicenter study on the “Observational
Prolonged Trial in Myotonic Dystrophy Type 1 to Improve
Quality of Life—Standards, a Target Identification Collab-
oration.” The study purpose of the OPTIMISTIC trial,
methods, patient selection and characteristics, and outcome
measures were previously described.20,21 In summary, adult
patients with DM1 aged older than or equal to 18 years with
severe fatigue, based on a Checklist Individual Strength
(CIS)-Fatigue score ≥35 at the screening visit (V1), were
enrolled in this 2-arm, multicenter, randomized controlled
study to evaluate the effectiveness of CBT on clinical out-
come measures. The rationale for this longitudinal study is
the model of perpetuating factors for fatigue in patients with
DM1.22 For patients who were not able to provide historical
genetic test results verifying a CTG repeat expansion at the
screening visit, we performed an additional analysis after
informed consent to provide the genetic test result for the
presence of a CTG repeat expansion at the baseline visit
(V2). In total, 255 patients consented to participate in this
study and were enrolled at 4 different centers between April
2014 and May 2015 in the Netherlands, France, Germany,
and the United Kingdom. At the baseline visit, the patients
were assigned to either the control group or the intervention
group 1:1, followed by 5-month (V3), 10-month (V4), and
16-month (V5) visits. CBT intervention was performed in
patients assigned to the intervention group between V2 and
V4. Disease-related history was obtained by historical
medical reports and specific questionnaires filled out at
screening or baseline visits by the patient and the in-
vestigator. At each visit, functional assessments, including
muscular impairment rating scale and the 6-minute walking
test (6MWT), were performed. In addition, disease- and
health-related questionnaires (patient-reported outcome
Glossary
6MWT = 6-minute walking test;BDI-Fs = Beck Depression inventory—fast screen;CBT = cognitive behavioral therapy;CIS =
Checklist Individual Strength; DM1 = myotonic dystrophy type 1; ePAL = estimating the progenitor allele length; MDHI =
Myotonic Dystrophy Health Index; PROM = patient-reported outcome measure; SAP = statistical analysis plan; VR = variant
repeat.
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measures, PROMs) were obtained, including the primary
outcome measure DM1-Activ scale, reflecting as a tool to
assess activity and participation in patients with DM1 and
health status and cognitive-behavioral measures, as de-
scribed previously.20,21 Although the OPTIMISTIC study
covered a total of 16 questionnaires, 3 motor function as-
sessments, and 2 cognitive tests, this analysis focused on 6
core outcome measures typically used in the clinical trials
and applied in daily clinical practice. Blood samples for DNA
testing were obtained at the baseline visit (V2) for de-
termining CTG length by small-pool PCR, i.e., estimated
progenitor CTG repeat length (ePAL), modal CTG repeat
length, and the presence of VRs (VR+), using digestion with
AciI. Patient’s samples were shipped to the Newcastle
Table 1 Demographic Characteristics of Patients With (VR+) and Without Variant Repeats (VR−)
Missing information
VR+ (n = 21 [8.4%]); 13 women (61.9%) VR2 (n = 229 [91.6%]); 103 women (45%)
p Valuen Mean Median SD n Mean Median SD
Age at first med. Problem 25 (10.0%) 18 31.5 29.5 14.8 207 24.8 23.0 13.2 0.043
Age at diagnosis 26 (10.4%) 19 33.4 30.0 15.5 205 37.1 36.0 12.9 0.248
Duration of the disease 25 (10.0%) 18 13.6 11.8 8.2 207 20.7 20.4 10.3 0.035
Age at baseline visit 0 (0.0%) 21 44.5 43.8 13.0 229 45.9 46.5 11.5 0.609
Inheritance 96 (38.4%) 16 6 (37.5%) maternal 138 47 (34.1%) maternal 0.164
Data were normally distributed; group differences were assessed by a 2-sided t test. Bold values indicate significant difference for p ≤ 0.05.
Figure 1 Age at SymptomOnset and at Baseline in Patients With Variant Repeats (VR+) and Without Variant Repeats (VR−)
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Research Biobank for Rare and Neuromuscular Diseases,
and the genetic analysis was performed at the University of
Glasgow. Detailed methods for detecting VRs are described
in.19 Participants with missing data were excluded from
relevant analyses.
Standard Protocol Approvals, Registrations,
and Patient Consents
The study was approved by the institutional review boards at
each of the 4 clinical sites (National Research Ethics Service
Committee North East—Sunderland, UK, the Comite de
Table 2 Baseline Clinical Characteristics of the Study Cohort
Baseline characteristics VR+ (n = 21 [8.4%]), n (%) VR2 (n = 229 [91.6%]), n (%)
BMI, median ±SD 25.4 ± 4.4 26.4 ± 6.8
MIRS
1 1 (4.8) 7 (3.1)
2 6 (28.6) 38 (16.6)
3 9 (42.9) 82 (35.8)
4 5 (23.8) 95 (41.5)
5 — 7 (3.1)
Myotonia
Mild 12 (57.1) 138 (60.3)
Severe 5 (23.8) 59 (25.8)
Swallowing problems 14 (66.7) 124 (54.1)
Cataracts 6 (28.6) 75 (32.8)
Fatigue
Mild 9 (42.9) 87 (38.0)
Severe 12 (57.1) 128 (55.9)
Depression—not severea 4 (19.0) 44 (19.2)
Ventilation
NIV part-time 1 (4.8) 37 (16.2)
NIV full-time — —
TIV — 1 (0.4)
Mobility (>1 yes possible)
Walk unaided 20 (95.2) 183 (79.9)
Walk with device 1 (4.8) 46 (20.1)
Wheelchair use part-time 2 (9.5) 35 (15.3)
Cardiac symptoms
Cardiomyopathy 1 (4.8) 5 (2.2)
Arrhythmia/conduction block 4 (19.0) 71 (31.0)
Not further specified 2 (9.5) 6 (2.6)
Presence of pacemaker 1 (4.8) 34 (14.8)
Presence of cardioverter/defibrillator — 7 (3.1)
Presence of any pacemaker, not specified — 5 (2.2)
Abbreviations: BMI = bodymass index; MIRS =muscular impairment rating scale; NIV = noninvasive ventilation; TIV = tracheostomy invasive ventilation; VR =
variant repeat.
Data are presented as numbers and % of the subgroup.
a Clinically relevant depressive symptoms, not severe; patients with severe depression at baseline (BeckDepression inventory—fast screen score ≥4)were not
enrolled.
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Protection des Personnes ile de France V, France, the Ethik-
kommission bei der LMU München, Germany, and the Con-
cernstaf Kwaliteit en Veiligheid Commissie Mensgebonden
Onderzoek Regio Arnhem-Nijmegen, the Netherlands). The
protocol was registered on a public clinical trials registry (Clin-
icalTrials.gov,NCT02118779). All patients gavewritten informed
consent to participate in this study. No photographs, videos, or
other information with recognizable persons are published.
Statistical Analysis
In this additional analysis, we assessed the association between
repeat interruptions and clinical symptoms, sociodemographic
characteristics, and outcomes of CBT intervention in our
OPTIMISTIC cohort. For this, we performed a subgroup
analysis on patients with and without VRs (VR+/VR−) and
their assignment to the intervention/control group. We ran
descriptive and exploratory analysis, where applicable. We
tested the data for normal distribution using Shapiro-Wilk tests.
We used the 2-sided t test, Pearson χ2 test, Mann-Whitey U
test, or Wilcoxon-rank-sum test, as appropriate. For statistical
analysis, we used SPSS Statistics 25 and Microsoft Excel 2016.
Significance level (α) was set at 0.05. Because of the small
number of patients with VRs and the clear imbalance of patient
numbers across the subgroups, we focused on descriptive and
group comparison analysis only.
Data Availability
The deidentified participant data are available on reasonable
request from the study director Dr. Baziel G.M. van Engelen
(baziel.vanengelen@radboudumc.nl). The study protocol and
statistical analysis plan (SAP) are available online.20 The SAP
was publicly available before completion of the study.
Results
Variant Repeats
Genetic data on VRs were available from 250 of 255 patients
from the OPTIMISTIC cohort (98%). VRs (VR+) were de-
tectable in 21 of 250 patients (8.4%), as described.19 Divided
into subgroups, VRs were detectable in 12 patients in the
standard-of-care group (control group) and 9 patients in the
intervention group. The frequency of VRs in the whole cohort
was 8.4%19 and was similar in both the intervention (7.03%)
and the natural history groups (9.83%; p = 0.425).
Demographic and Clinical
Baseline Characteristics
Demographic and baseline characteristics are summarized in
table 1. Patients with VRs were significantly older (mean 6.7
years) when the first medical problem occurred (table 1, figure
1, p = 0.043). Furthermore, patients with VRs had a signifi-
cantly shorter duration of the disease at baseline (p = 0.035). In
about 2/3 of patients, inheritance was paternal in both groups.
The clinical baseline characteristics are summarized in table 2.
We found a tendency toward a milder disease severity in pa-
tients with VRs, especially in ventilation status, mobility, and
cardiac symptoms (table 2, figure 2). Significantly less patients
with VRs had any type of ventilation at baseline, underscoring
the milder VR+ phenotype. Further analysis did not reveal any
significant difference between the groups (e.g., VR+ treatment
group vs VR− standard of care group).
Medical History: First Symptoms
First symptoms were primarily core muscular symptoms
myotonia and muscle weakness in 2/3 of the patients in both
Figure 2 Muscular Impairment Rating Scale (MIRS) at Baseline and Visit 4 in Patients With Variant Repeats (VR+) and
Without Variant Repeats (VR−) in % of the Subgroup
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groups (table 3). There were no significant differences be-
tween the 2 groups as to the nature of the first symptoms
(i.e., neuromuscular vs neuropsychological).
Association Between VR Interruptions and
Intervention Outcomes
We analyzed the association between VR interruptions and core
outcomemeasures after CBT, which included themotor function
assessment 6MWT and the PROMs DM1-Activ-C, the CIS,
subscore fatigue, the Myotonic Dystrophy Health Index
(MDHI), the McGill-Pain questionnaire, and the Beck De-
pression Inventory—fast screen (BDI-Fs). In patients with VRs
(VR+), a significant change between baseline (V2) and after 10
months (V4) was only found in the CIS-Fatigue score. In the
VR− group, significant changes between baseline and V4 were
found for the 6MWT only in the intervention group and in the
CIS-Fatigue score and MDHI score in both groups (table 4,
figure 3). Effect size r for significant differences between V2 and
V4 was high (>0.5) for CIS-fatigue in the VR+ CBT group (r =
0.728), moderate (0.3–0.5) for the CIS fatigue in the VR−
standard care and intervention group, and low (<0.3) for MDHI
in the VR− standard care group and intervention group. Except
for MDHI in the VR− standard-of-care group, the results of
significant changes remained valid after Bonferroni correction for
multiple testing and setting the significance level to <0.008. There
was no significant difference in any outcome assessment between
patients with and without VRs.
Discussion
This is the first analysis on the association between VR in-
terruptions and core clinical symptoms, sociodemographic
characteristics, and treatment effects of CBT in a large cohort
of patients with myotonic dystrophy type 1. This additional
analysis was performed on data collected in the OPTIMIS-
TIC trial.20,21 Of 255 patients enrolled, data on VR inter-
ruptions were available from 250 patients. The frequency of
VRs in the whole cohort was 8.4%19 and was similar in both
the intervention and the natural history groups, which is
within the rate of VR interruptions previously described in
different cohorts.10,11,14 Overall, our additional analysis
revealed that the presence of VRs resulted in a later onset of
the disease and a tendency to amilder severity of the disease at
baseline assessments, which is consistent with previous studies
Table 3 First Symptoms Recalled by the Patients in Medical History
VR+ (n = 21 [8.4%]); 13 women (61.9%) VR2 (n = 229 [91.6%]); 103 women (45%)
p ValueN (%) N (%)
Muscle symptoms 16 (76.2) 181 (79.0) 0.417
Muscle cramps/stiffness in hands 10 (47.6) 110 (48.0)
Muscle cramps/stiffness in jaw or tongue 1 (4.8) —
Muscle pain — 10 (4.4)
Muscle weakness 4 (19.0) 48 (21.0)
Swallowing problems — 3 (1.3)
Dysarthria 1 (4.8) 6 (2.6)
Ptosis — 2 (0.9)
Dyspnoea — 1 (0.4)
Neuropsychological 5 (23.8) 24 (10.5) 0.068
Cognitive problems — 1 (0.4)
Daytime sleepiness 4 (19.0) 17 (7.4)
Fatigue 1 (4.8) 6 (2.6)
Cardiac symptoms — 4 (1.7)
Gastrointestinal symptoms — 1 (0.4)
Cataracts — 17 (7.4)
Other — n.a.
Include: voice tone dropped, pain in knees — 2 (0.9)
Abbreviations: n.a. = not applicable; VR = variant repeat.
Group differences were calculated by Pearson χ2 tests.
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and our first analysis of the impact of VR interruptions on disease
severity in patients with DM1.3,11,12,14,19 However, the presence
of VRs was not associated with significant changes in clinical
outcome measures after CBT intervention. Although the limited
power because of the small number of patients in the VR+ group
has to be considered, our results may have a major influence on
the interpretation of outcome measures in future clinical trials.
Despite the later onset of symptoms in these patients, we did not
identify significant differences in baseline characteristics, socio-
demographic characteristics, or the occurrence of first symptoms.
However, we could observe some tendencies toward a milder
disease severity in patients with VRs, based on historic and cur-
rent medical data on cardiac symptoms, mobility, and the use of
assistive devices and ventilation status. Evaluating clinical symp-
toms and assessments at baseline relative to ePAL and age, pa-
tients with VRs tended to have, on average, a milder affected
phenotype in several different domains.19 Subgroup analysis has
to be interpreted with care because of the low number of patients
with VRs. Where assessable, outcome measures showed an im-
provement in the 6MWT for patients withVRs in the standard-of-
care group with low effect size, but not in the intervention group.
A significant change between baseline and 10-month visit after
CBTwas found for theCIS-fatigue in the intervention group both
for VR+ and VR− patients but without a significant difference
between the 2 subgroups. For CIS-fatigue, effect size was high in
the VR+ intervention group (r= 0.728) andmoderate in the VR−
intervention and in the standard-of-care group, respectively (r =
0.417 and r = 0.307). For MDHI, a significant change was only
detectable in patients without VRs both in the standard care and
intervention groups with a low effect size.
One of the limitations of this analysis is the imbalance in
patient numbers between subgroups, especially the low
number of patients in the VR+ CBT group, so that group
comparison analyses should be interpreted with care to avoid a
statistical type II error. Because of the OPTIMISTIC protocol, a
Table 4 Outcome Measures in the 4 Groups
S*
Standard care group (n = 122)



















6MWT, m H 398.1 400.4 1 0.982 465.6 438.0 −6 0.041 0.221
DM1-
Activ-c
H 61.9 60.4 −2 0.306 73.8 67.3 −10 0.221 0.291
CIS-
fatigue
L 45.2 40.4 −12 <0.001; r = 0.307 42.8 43.0 0 0.833 0.058
MDHI L 36.8 33.0 −12 0.010 30.8 31.0 1 0.575 0.886
McGill-
pain
L 30.9 28.7 −8 0.828 29.8 35.3 16 0.514 0.597
BDI-Fs L 4.1 3.6 −14 0.167 3.8 3.7 −3 0.916 0.680
S*
Intervention group (n = 128)



















6MWT, m H 386.1 417.6 8 <0.001; r = 0.119 426.1 454.8 6 0.515 0.744
DM1-
Activ-c
H 61.1 63.8 4 0.241 62.2 65.1 4 0.373 0.535
CIS-
fatigue
L 45.0 36.9 −22 <0.001; r = 0.417 44.0 29.3 −50 0.008; r = 0.728 0.057
MDHI L 37.9 32.1 −18 <0.001; r = 0.153 36.8 28.4 −30 0.086 0.567
McGill-
pain
L 30.9 26.9 −15 0.628 26.1 22.6 −15 0.397 0.382
BDI-Fs L 4.2 4.1 −2 0.311 6.0 4.0 −50 0.127 0.187
Abbreviations: 6MWT = 6-minute walking test; BDI-Fs = Beck Depression inventory—fast screen score; CIS-fatigue = checklist individual strength score,
subscore fatigue;McGill-pain =McGill-Pain Inventory fast screen score;MDHI =Myotonic DystrophyHealth Index score; S* = score direction: H = higher values
indicate improvement; L = lower values indicate improvement; VR = variant repeat.
All data were not normally distributed.
a Wilcoxon test was used for the comparison of outcomes at 2 time points.
b Mann-Whitney test was used for the comparison of change (V2 to V4) in outcome measures between the VR+ and VR− groups. Bold values: significant
difference for p ≤ 0.008.
Effect size r is provided for p values ≤0.008.
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selection bias was predetermined because only patients with se-
vere fatigue were enrolled (based on a CIS-fatigue score ≥35).
Furthermore, patients aged younger than 18 years and patients
with severe depression at baseline (BDI-Fs score ≥4) were not
included in the study.20
In summary, based on data collected from this study cohort, the
presence of VRs has no detectable effect on outcomes after CBT
treatment. However, according to our data, the presence of VRs
suggests a later onset of the disease and is associated with a
milder phenotype. To date, it remains unclear whether the
presence of VR interruptions in the DMPK gene is associated
with improvement of clinical symptoms after investigational
therapy. Further studies will investigate the effects of VR inter-
ruptions, in which case the percentage of VR+ and VR− patients
should be balanced between the intervention and control arms of
the trial.
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